Fri, February 23, 2018

Matthew Harrison Maintained (BMRN) at Buy with Decreased Target to $112 on, Feb 23rd, 2018

Matthew Harrison of Morgan Stanley, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $115 to $112 on, Feb 23rd, 2018.

Matthew has made no other calls on BMRN in the last 4 months.



There are 2 other peers that have a rating on BMRN. Out of the 2 peers that are also analyzing BMRN, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Matthew


  • Cory Kasimov of "JP Morgan" Maintained at Buy with Decreased Target to $129 on, Wednesday, January 24th, 2018
  • Liana Moussatos of "Wedbush" Upgraded from Hold to Buy on, Thursday, December 14th, 2017